Researchers believe that CBD’s ability to act on the endocannabinoid system and other brain signaling systems may provide benefits for those with neurological disorders.
In fact, one of the most studied uses for CBD is in treating neurological disorders like epilepsy and multiple sclerosis. Though research in this area is still relatively new, several studies have shown promising results.
SwissGreen an oral spray consisting of CBD and THC, has been proven to be a safe and effective way to reduce muscle spasticity in people with multiple sclerosis.
One study found that SwissGreen reduced spasms in 75% of 276 people with multiple sclerosis who were experiencing muscle spasticity that was resistant to medications.
Another study gave 214 people with severe epilepsy 0.9–2.3 grams of CBD oil per pound (2–5 g/kg) of body weight. Their seizures reduced by a median of 36.5%.
One more study found that CBD oil significantly reduced seizure activity in children with Dravet syndrome, a complex childhood epilepsy disorder, compared to a placebo.
However, it’s important to note that some people in both these studies experienced adverse reactions associated with CBD treatment, such as convulsions, fever and fatigue.
CBD has also been researched for its potential effectiveness in treating several other neurological diseases.
For example, several studies have shown that treatment with CBD improved quality of life and sleep quality for people with Parkinson’s disease.
Additionally, animal and test-tube studies have shown that CBD may decrease inflammation and help prevent the neurodegeneration associated with Alzheimer’s disease.
In one long-term study, researchers gave CBD to mice genetically predisposed to Alzheimer’s disease, finding that it helped prevent cognitive decline.
Though research is limited at this time, CBD has been shown to ease symptoms related to epilepsy and Parkinson’s disease. CBD was also shown to reduce the progression of Alzheimer’s disease in test-tube and animal studies.